Enforced polarization of melanoma cells towards a JARID1B-high phenotype exhausts tumour fitness
Heike Chauvistré(Essen University Hospital), Nikolas K. Haass(The University of Queensland), Felix C. E. Vogel(German Cancer Research Center), Batool Shannan(Vrije Universiteit Brussel), Alexander Roesch(Essen University Hospital), Meenhard Herlyn(The Wistar Institute), Q. Liu, Dirk Schadendorf(National Center for Tumor Diseases), Clemens Krepler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Oliver Keminer(Fraunhofer Institute for Translational Medicine and Pharmacology), Marc Remke(Saarland University), Claudia Becher, A. Hoewner(University of Duisburg-Essen), Şule Karabulut Gül, Daniel Picard(Heidelberg University), Andrea Sechi(Ospedale San Bortolo), N. Lorberg, Sheena M. Daignault(The University of Queensland), D. Zarschler
RWTH Publications (RWTH Aachen)
January 1, 2017
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k